Participated · Seed · Jan 2019

Perfuze develops next-generation catheter-based aspiration technology to treat acute ischemic stroke, with a proprietary platform designed to maximize clot removal efficiency and simplify procedures. The company’s Zipline™ Access Catheters, cleared by the FDA via 510(k), are engineered to improve trackability and deliver large (070) and superbore (088) aspiration catheters. Perfuze has initiated a Limited Market Release in U.S. Comprehensive Stroke Centres and is rolling out the Zipline™ alongside its Millipede™ catheters. The company is headquartered in Galway, Ireland, and emphasizes faster, easier navigation to accelerate reperfusion and improve clinical outcomes. Recent funding will support the U.S. Limited Market Release, ongoing clinical programs, and R&D to further enhance its stroke-treatment portfolio. Perfuze develops super-bore diameter aspiration catheter technology (the Millipede System) intended to navigate complex neurovascular anatomy and enable fast, complete clot removal in acute ischemic stroke. The company holds CE Mark approval for its first device, Millipede 088, and has treated its first cohort of patients. Proceeds from the Series A will fund the next stage of U.S. clinical study and regulatory clearance of the Millipede System, support ongoing product development, and initiate commercialization. Perfuze’s pipeline is focused on devices designed to shorten procedural times and improve clinical outcomes in large vessel occlusion stroke. The company was founded in 2018 by Wayne Allen and Liam Mullins and is based in Galway, Ireland. Perfuze is developing the Millipede platform, a next-generation catheter-based technology intended to treat acute ischemic stroke. The technology aims to deliver superior clinical outcomes in shorter procedural times, providing safe, cost-effective therapy. The company closed a €3 million seed investment to facilitate further development of the Millipede platform. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins, who together have over 30 years of medtech experience. The company is based at the Business Innovation Centre on the campus of the National University of Ireland, Galway and is relocating to the IDA Business Park in Dangan, Galway.

Participated · Series B · Jan 2015

Vascular Dynamics (VDI), based in Irvine, Calif., is a privately held medical device company developing endovascular, device-based solutions for heart failure patients. Its lead product, the MobiusHD, is an endovascular implant designed to reshape the carotid artery and amplify the body’s natural baroreflex to modulate the autonomic nervous system and improve heart function. Clinical evaluations of MobiusHD are in progress, including a feasibility study that recently enrolled its 30th patient. Initial 12-month clinical results have shown impressive efficacy and indicated the device provides a safe option for treating symptomatic heart failure patients. Management says the new financing will enable expansion of the pilot study and prepare the company for a forthcoming pivotal study. The company emphasizes minimally invasive, transcatheter delivery to treat patients who remain symptomatic despite medical therapy. Vascular Dynamics is a Mountain View, CA-based medical device company led by president and CEO Robert Stern that develops catheter-delivered technologies for resistant hypertension. Its lead product is the investigational MobiusHD system, which is covered by nine issued and numerous pending U.S. and international patents. The MobiusHD device recently received CE Mark but is not commercially available in the United States. The company has been accepted into the FDA’s Feasibility Study IDE program and its Expedited Access PMA program. Vascular Dynamics completed a $10.4M financing and intends to use the proceeds to conduct studies for the MobiusHD system. Vascular Dynamics develops minimally invasive medical devices for the treatment of refractive or resistant hypertension. Its core product, MobiusHD, is a catheter-delivered nitinol implant placed endovascularly at the carotid sinus designed to amplify signaling to arterial baroreceptors and thereby dilate peripheral blood vessels to reduce blood pressure. The company is conducting clinical trials in the U.S. and Europe to evaluate the safety and performance of the MobiusHD device. VDI intends to use the new funds to advance this clinical trial program in both the United States and Europe. Led by President and CEO Robert Stern, the company raised $8.425m as the first tranche of its Series B, with a planned total Series B of $16.85m. To date, Vascular Dynamics has raised a total of $23m across its Series A and Series B financings.

Participated · Series C · Aug 2011

Ellipse Technologies is a privately held medical device company in Irvine, California focused on implantable remote-control technology for spinal and orthopedic deformity, trauma, and fracture management. Its core products are the MAGEC System (MAGnetic Expansion Control) for non-invasive adjustment of spinal implants and the PRECICE remote-control intramedullary rods for limb lengthening. Both MAGEC and PRECICE are CE‑Marked; MAGEC was launched at IMAST and PRECICE was displayed at the LLRS meeting, and the company has initiated clinical use outside the U.S. with planned international rollouts. Ellipse holds issued and pending patents covering its remote-control platforms and is developing additional devices for other orthopedic applications. The company recently completed a $17.6 million Series C financing to enable commercialization of MAGEC and PRECICE and to fund expanded uses of its patented technologies into new markets.

Participated · Series B · Mar 2010

Reverse Medical Corporation is an Irvine, CA–based medical device company that develops patented technologies for treating and preventing acute ischemic strokes. Its core product is a microcatheter for performing thrombectomy. The company completed a $14M Series B private equity financing to support its operations. The capital infusion is intended to allow the company to continue its progress toward commercialization and profitability. Reverse Medical was founded and incubated by The MedFocus Fund. Both new and existing investors participated in the round.